

Cardiovascular Phase 4: 2016 – 2017 Project

*Standing Committee
Measure Evaluation Q&A Call*

*Melissa Mariñelarena/ Senior Director
Wunmi Isijola/ Administrative Director
Donna Herring/ Project Analyst*



NATIONAL
QUALITY FORUM



eMeasures Overview

eMeasures Overview

- NQF accepts submissions for three categories of Electronic Clinical Quality Measures (eCQMs):
 - *De Novo* - Brand new eCQMs; must adhere to NQF's measure submission and testing process
 - *Legacy eCQMs* – Current NQF endorsed measures being used in national quality improvement programs and are being respecified into eCQMs; can use BONNIE for testing
 - *Trial Approval* – Measures are submitted for consideration into the NQF Trial Approval Program

eMeasures Overview

This project will review one *Legacy* eMeasure

2906 : Prostate Cancer: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)

- This measure is the new eMeasure version of measure NQF #0070. #0070 was discussed during CV Phase 3 in 2015.

Questions?



NATIONAL
QUALITY FORUM



SDS Trial Period Overview

Background

- During a **two-year trial period**, adjustment of measures for socio-demographic (SDS) factors **will no longer be prohibited**
- Each measure must be assessed individually to determine if SDS adjustment is appropriate
- The Standing Committee will continue to evaluate the measure as a whole, including the appropriateness of the risk adjustment approach used by the measure developer
- Efforts to implement SDS adjustment may be constrained by data limitations and data collection burden

Standing Committee Evaluation

- The Standing Committee will be asked to consider the following questions:
 - Is there a conceptual relationship between the SDS factor and the measure focus?
 - What are the patient-level sociodemographic variables that were available and analyzed during measure development?
 - Does empirical analysis (as provided by the measure developer) show that the SDS factor has a significant and unique effect on the outcome in question?
 - Does the reliability and validity testing match the final measure specifications?

SDS Overview

This project will review one outcome measures that should include SDS factors or conceptual SDS analysis:

- 0076 : Optimal Vascular Care

Questions?



NATIONAL
QUALITY FORUM

Next Steps

- Committee Preliminary Evaluations– Due by June 28th
- In-person Meeting in Washington D.C – July 12
- Post In-Person Meeting Call– July 20: 3-5pm ET